A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

People seeking weight-loss medication on the NHS are being warned it is not yet available in Derbyshire and only a very ...

Boots Online Doctor has revealed the 'very common' side-effects of Mounjaro you need to know about after thousands of people ...

A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

The NHS has just announced a major change made to Mounjaro access as 1,600,000 people are now expected to receive the weight ...